YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM L... (uzumab's survival benefit in combination...)

HOME >> BIOLOGY >> TECHNOLOGY

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

Date:1/5/2009

uzumab's survival benefit in combination with external radiotherapy in patients diagnosed with stage IIb, III NSCLC who are ineligible for treatment with radical chemoradiotherapy or in stage IV NSCLC patients with chest disease including those eligible for palliative radiotherapy. The trial will enroll approximately 128 patients over 18 months followed by an 18 month follow-up period and will likely include 20 investigational centers in Canada plus additional centers in other countries. Nimotuzumab will be administered weekly, starting on the first day of radiotherapy, until disease progression. Chemotherapy may be provided to patients in either arm at the discretion of the physician.

The design of the trial was supported by data presented at ASCO 2008 from the Canadian arm of a fully recruited lead-in Phase I trial treating patients with NSCLC palliatively. That trial was conducted in Canada by YM and in Korea by Kuhnil Pharmaceutical Co. The ASCO data indicated that the combination of nimotuzumab with radiation has the potential to provide an important quality of life and survival advantage to patients over radiation alone in the palliative setting. Substantial radiological responses and meaningful clinical responses were seen inside and outside the radiation field in patients treated with the combination of nimotuzumab and radiation. Continued treatment for prolonged periods was very well tolerated and there was no evidence of grade III or IV rash at any of the three dose levels. The Canadian cohort had a median survival of 13.8 months, which compares very favorably with historical data (Brundage Can J Oncol. 1996 Feb; 6 Suppl 1:25-32.; Bezjak Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):719-28; Sundstrom J Clin Oncol. 2004 Mar 1;22(5):801-10).

"Numerous NSCLC patients undergo radiotherapy because they are unfit for radical chemoradiotherapy or require radiotherapy palliatively for their chest disease either as part of their initial management
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:

(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader in the ... of the cutting-edge science behind its lead oncology ... world rediscovered the Cyclin G1 gene ... and disease progression, and thus a prime target ... National Cancer Institute investigating the role of microRNAs ...

(Date:12/15/2009)... -- Repligen Corporation (Nasdaq: RGEN ) today ... research funding to support the ongoing development of ... Dystrophy Association (MDA). This grant will support ... GMP manufacture of a drug candidate for human ... only provides important funding for Repligen,s research but ...

(Date:12/15/2009)... NEW YORK, Dec. 15 Reportlinker.com ... is available in its catalogue: ,, ... - Market Forecasts to 2015, Pipeline Analysis ... http://www.reportlinker.com/p0168104/The-Future-of-Orphan-Diseases-Therapeutics---Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html ,, Summary ... latest research "The Future of Orphan Diseases ...

(Date:12/15/2009)... CHARLOTTESVILLE, Va., Dec. 15 AstraZeneca ... University of Virginia (UVa) in Charlottesville, today ... strategic research collaboration to enhance development of ... (CAD) with a secondary focus on peripheral ... ) ,, The collaborative preclinical research ...

[0] Scientists Rediscover Gene Target for Cancer Therapy [0] Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich's Ataxia Preclinical Development Program [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease

... race to make solar cells cheaper and more ... on new designs that exploit nanostructures--materials engineered on ... Using nanotechnology, researchers can experiment with and control ... free electrons--properties that are important for the conversion ...

... to CMM for,Professional Services in Finding Genetic Markers ... Jan. 8 The Center for Molecular,Medicine (CMM) ... Children,s,Oncology Group (COG) to provide professional genotyping services ... the existence of genetic,abnormalities and their association with ...

... Jan. 8 Substantial progress and,momentum behind its research-and-development ... deliver several new blockbuster products to farmers,by 2012, company ... part of a series of presentations on the company,s ... to see such innovation in the pipeline right now," ...

Other Biology Technology:New nanostructured thin film shows promise for efficient solar energy conversion 2 New nanostructured thin film shows promise for efficient solar energy conversion 3 Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study 2 Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study 3 Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study 4 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 2 Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade 3

New nanostructured thin film shows promise for efficient solar energy conversion Center for Molecular Medicine Selected to Provide DNA Analysis for Children's Oncology Group Leukemia Study Monsanto's R&D Pipeline Set to Deliver Valuable Products to Farmers Well Into Next Decade

(Date:12/16/2009)... Chu announced today the winners of the 2009 E.O. ... development supporting the Department of Energy and its missions. ... gold medal, a citation and $50,000. Winners ... early next year., "The contributions made by these researchers ... the United States are wide-ranging and meaningful," Secretary Chu ...

(Date:12/16/2009)... determined that short-term, seasonal exposure to pesticides in ... size of wild salmon populations. In addition to ... suggest that exposure to commonly used pesticides may ... populations. , "Major efforts are currently underway ... to recover depressed populations," says David Baldwin of ...

(Date:12/16/2009)... Calif., Dec. 1 GestureTek Inc. ... Release 3.0 - a turnkey, portable, plug ... advertising, exhibits, entertainment and touring promotions. GestureTek ... of patents in camera-enabled gesture recognition technology ... ,, Guaranteed for quality, the CUBE has ...

Breaking Biology News(10 mins):Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners 2 Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2 GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 3 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 1 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 2 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 3 Dr Siegals Cookie Diet Book Cracks the Amazon Top 500 60007 4 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 1 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 2 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 3 Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 4 Keraderm Closes on 242 5 Million Investment from NewVa Capital Partners LP 5664 1 Keraderm Closes on 242 5 Million Investment from NewVa Capital Partners LP 5664 2 Keraderm Closes on 242 5 Million Investment from NewVa Capital Partners LP 5664 3

[0] Secretary Chu announces 2009 Ernest Orlando Lawrence Award winners [0] Even at sublethal levels, pesticides may slow the recovery of wild salmon populations [0] GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits

... quantifying the role of forests in the carbon ... predictors of forest biomass and carbon flux. Over ... generated testable explanations, derived from physical and biochemical ... However, in two Ecology Letters articles, Helene Muller-Landau ...

... their skeletons using a toothbrush, the Norwegians found one using a ... the North Sea, at an entire 2256 metres below the seabed. ... the time the North Sea wasn't a sea at all, but ... the remains of the old dinosaur now see the light of ...

... may cringe at the idea, but sperm-producing stem cells found ... frozen for future use. A team in the Netherlands has ... inside mouse testes. The hope is that the same thing ... route to help young cancer patients undergoing chemotherapy," Dirk de ...

Other Biology News:Diverse tropical forests defy metabolic ecology models 2 Diverse tropical forests defy metabolic ecology models 3 Diverse tropical forests defy metabolic ecology models 4 Testes to incubate stem cells 2

Diverse tropical forests defy metabolic ecology models The world's deepest dinosaur finding - 2256 metres below the seabed Testes to incubate stem cells

BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....

... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...

... as an internal standard for the quantification ... spectrometry. 5-OxoETE is a polyunsaturated keto acid ... human neutrophils. It stimulates cytosolic calcium levels ... nM. 5-OxoETE selectively stimulates the migration and ...

... These protein size markers are a ... from 16 to 100 kDa. The markers ... SDS-polyacrylamide gels after staining with Coomassie blue. ... Strep•Tag II sequence, the markers can also ...

Biology Products:

BD BioCoat Gelatin 100 mm Culture Dishes from BD Biosciences - Discovery Labware 5-OxoETE-d7, Deuterium Conjugated/Tagged from Cayman Chemical 5-OxoETE-d7, Deuterium Conjugated/Tagged from Cayman Chemical Strep•Tag^® II Perfect Protein™ Markers, 16–100 kDa, Lyophilized from Novagen

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM L...(uzumab's survival benefit in combination...)